Amphastar Pharmaceuticals AMPH Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.42M-74.6% | $24.43M-35.7% | $17.35M-57.1% | $31.03M-18.2% | $25.29M-41.4% | ||
| $8.08M+9.6% | $8.07M+11.2% | $7.86M+8.8% | $8.35M+20.0% | $7.37M+8.1% | ||
| $9.27M+10.5% | $6.21M+10.2% | $6.3M+12.5% | $6.38M+10.4% | $8.39M+14.0% | ||
| $761K-0.1% | $866K+19.6% | $885K+19.0% | $842K-65.4% | $762K-64.2% | ||
| -$4K-100% | -$6K— | -$1K+50.0% | -$30K— | -$2K— | ||
| $4.55M-43.7% | —— | $13.79M+71.2% | -$12.27M— | $8.08M-65.2% | ||
| -$6.25M-120% | —— | —— | $4.82M-31.4% | $31.11M+211% | ||
| $9.6M-45.5% | -$42.64M-2,119% | $25.34M+2.8% | -$4.86M-135% | $17.61M-23.7% | ||
| $2.33M+174% | —— | $7.94M-26.0% | $4.57M+1,155% | $849K+342% | ||
| $6.27M+0.5% | $6.27M+1.5% | $6.27M+1.5% | $6.27M+1.2% | $6.24M+1.2% | ||
| $2.14M+34.2% | $1.65M+34.0% | $1.64M+58.7% | $1.62M+62.8% | $1.6M+63.1% | ||
| $47.84M+36.4% | $32.86M+13.2% | $52.58M-12.3% | $35.59M-48.5% | $35.08M-36.6% | ||
| $9.51M-11.1% | $8.27M-33.3% | $5.35M-61.2% | $10.57M+74.8% | $10.7M+21.7% | ||
| -$16.73M-260% | -$60.57M-69.8% | -$19.62M+43.3% | -$625K+99.1% | $10.48M-31.2% | ||
| $29.49M+168% | $20.52M-51.2% | $4.85M-86.1% | $39.22M— | $11M— | ||
| —— | —— | $172K-98.2% | $4.13M— | $1.64M-59.8% | ||
| $29K-23.7% | $104K-9.6% | $44K+7.3% | $37K-99.5% | $38K-61.2% | ||
| —— | $8K— | $4K-99.3% | $253K— | $422K+67.5% | ||
| -$30.21M-108% | -$18.37M+45.7% | -$4.35M+80.9% | -$30.2M-182% | -$14.5M-6.8% | ||
| -$138K-217% | —— | —— | $142K+847% | $118K+222% | ||
| $762K-97.6% | —— | $28.58M+1,044% | $4.91M— | $31.17M-45.2% | ||
| $7.3M-3.8% | $4.08M-7.7% | $7.47M-12.5% | $4.09M-21.8% | $7.58M-12.2% | ||
| -$4.11M-356% | $402K-96.4% | $10K-99.9% | $23.2M+39.9% | -$902K-358% | ||
| $761K-0.1% | —— | —— | —— | $762K-64.2% | ||
| $6.27M+0.5% | $6.27M+1.5% | $6.27M+1.5% | $6.27M+1.2% | $6.24M+1.2% | ||
| $8.08M+9.6% | $8.07M+11.2% | $7.86M+8.8% | $8.35M+20.0% | $7.37M+8.1% | ||
| -$4K-100% | -$6K— | -$1K+50.0% | -$30K— | -$2K— | ||
| -$7.74M-19.7% | $20.5M+271% | —— | $14.94M+253% | -$6.47M-62.1% | ||
| $2.33M+174% | —— | $7.94M-26.0% | $4.57M+1,155% | $849K+342% | ||
| $2.14M+34.2% | $1.65M+34.0% | $1.64M+58.7% | $1.62M+62.8% | $1.6M+63.1% | ||
| -$1.42M-87.7% | -$1.66M-87.3% | -$1.59M-64.4% | -$1.61M-69.1% | -$754K+20.4% | ||
| —— | $8K— | $4K-99.3% | $253K— | $422K+67.5% | ||
| $4.17M-42.2% | $1.21M+142% | $474K— | —— | $7.22M+21.5% | ||
| $416K+119% | —— | —— | —— | -$2.14M-146% | ||
| $30.71M+5,794% | —— | $2.02M+216% | —— | $521K— | ||
| -$67K-472% | $434K-70.4% | $1.59M+50.6% | $2.32M+264% | $18K-98.1% | ||
| $686K-85.4% | —— | —— | —— | $4.69M-72.9% | ||
| -$4.11M-356% | —— | —— | —— | -$902K-358% | ||
| $38.33M+57.2% | $24.59M+48.0% | $47.24M+2.3% | $25.03M-60.3% | $24.38M-47.6% | ||
| $38.33M+57.2% | $24.59M+48.0% | $47.24M+2.3% | $25.03M-60.3% | $24.38M-47.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Amphastar Pharmaceuticals generate?
- Amphastar Pharmaceuticals (AMPH) generated $168.9M in operating cash flow over the trailing twelve months.
- What is Amphastar Pharmaceuticals's free cash flow?
- After $33.7M of capital expenditures, Amphastar Pharmaceuticals's free cash flow was $135.2M over the trailing twelve months, down 10.0% year over year.
- Where does Amphastar Pharmaceuticals's cash flow data come from?
- Every line is extracted from Amphastar Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
